title: Summary of presentations from the 46th Annual Meeting of the American Society of Clinical Oncology (2010) focus on tumor biology and biomarkers related to lung cancer.
abstract: Globally, lung cancer remains the most common cause of cancer-related death. In recent years, it has become clear that development of rational molecular targeted therapies is critical to improve the outcomes of patients with lung cancer. A better understanding of the tumor biology is crucial to achieve this goal. Several new findings in the field of tumor biology were presented at the 46th Annual Meeting of the American Society of Clinical Oncology. Novel genetic mutations were identified in pleural mesothelioma using array-based technologies. Several studies on the development and testing of new molecular diagnostic tests to detect epidermal growth factor receptor tyrosine kinase mutations and EML4-ALK (Echinoderm Microtubule-associated Protein like 4 Anaplastic Lymphoma Receptor Tyrosine Kinase) fusion gene were presented as well.
authors.affiliation: Division of Oncology, Department of Medicine, Washington University School of Medicine, St Louis, Missouri, USA.
authors.forename: Janakiraman
authors.initials: J
authors.lastname: Subramanian
authors.forename: Luis
authors.initials: L
authors.lastname: Corrales
authors.forename: Denis
authors.initials: D
authors.lastname: Soulieres
authors.forename: Daniel
authors.initials: D
authors.lastname: Morgensztern
authors.forename: Ramaswamy
authors.initials: R
authors.lastname: Govindan
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D014408:Biomarkers, Tumor / Q000037:antagonists & inhibitors* / Q000235:genetics / Q000378:metabolism; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000235:genetics / Q000378:metabolism*; D008495:Medical Oncology; D058990:Molecular Targeted Therapy
chemical_list: D000970:Antineoplastic Agents; D014408:Biomarkers, Tumor